William Blair has begun coverage of Xencor (XNCR, Financial) with an Outperform rating, highlighting the promising prospects of the biopharmaceutical manufacturer. The firm is optimistic about the industry's progression into a pivotal phase marked by significant advancements in T-cell engager development for solid tumors.
Central to Xencor's potential success is its XmAb platform. This innovative technology has already proven its viability through Amgen’s xaluritamig and is poised to be a cornerstone for Xencor's internally developed initiatives. William Blair's analysis suggests that XmAb819, a key asset targeting renal cell carcinoma, could achieve significant commercial success. This is attributed to its novel mechanism and its capacity to work synergistically with existing approved therapies in earlier treatment stages.
William Blair has assigned a net present value of $473 million, equating to $6.26 per share, to XmAb819. The firm believes that with the right strategic developments, this asset has the potential to become a blockbuster in the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Xencor Inc (XNCR, Financial) is $30.25 with a high estimate of $40.00 and a low estimate of $22.00. The average target implies an upside of 211.86% from the current price of $9.70. More detailed estimate data can be found on the Xencor Inc (XNCR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Xencor Inc's (XNCR, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Xencor Inc (XNCR, Financial) in one year is $12.72, suggesting a upside of 31.13% from the current price of $9.7. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Xencor Inc (XNCR) Summary page.
